CD19 and acute lymphoblastic leukemia: An ongoing Phase I clinical trial (NCT00840853) has studied VSTs genetically engineered to express CD19-redirected CARs to see if these cells can maintain their antiviral activity alongside exhibiting specific tumoricidal functionality in patients with CD19+ B-ALL after HSCT (142).